Therapeutic modalities of human β defensin-2 with prospective significance in diabetic wound treatment

Diabetic Wounds (DW) are a debilitating complication of diabetes. Although various therapeutic strategies are available for DW management, none of them meet all the fundamentals due to the multifaceted pathophysiology of DW. Given the ever-present threat of DW, novel improved therapeutic strategies and the fortification of DW research deserve better prioritization. The current review aims to provide the detailed role of human β defensin-2 (HBD-2) in skin wounds with a prospective significance in DW treatment. This review was conducted through searches of relevant abstracts, research and review articles, and patents, in Scopus, Web of Science, PubMed, Google Scholar, and Clinical Trials databases of English language articles. HBD-2 is a critical innate immune-response protein that defends the human body from infections. Recent reports also support the role of HBD-2 in suppressing inflammation and promoting proliferation and angiogenesis. Based on the literature, its therapeutic administration has been proposed to maintain the equilibrium of systemic homeostasis in DW. It has been hypothesized that HBD-2 could be a crucial modulator for controlling chronic inflammation and size by promoting proliferation and angiogenesis, opening up new therapy options in DW.